PMC5818949_01
PMC5818949_02
Graphical illustration of aHUS patient's clinical course and treatment. Clinical relapses depicted by red arrows.
CRIN2018-2781789.001.jpg
PMC5818949_02_CRIN2018-2781789.001.jpg
fig1
Clinical, haematological, and biochemical improvement occurred within 2-3 days of eculizumab infusion with each relapse (Figure 1).